Ocular Therapeutix Inc
NASDAQ:OCUL
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
5.925
16.11
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Gross Margin
Ocular Therapeutix Inc
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Ocular Therapeutix Inc
NASDAQ:OCUL
|
2.7B USD |
89%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
1T USD |
83%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
56%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
496.6B USD |
68%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
259.2B CHF |
74%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
212B GBP |
82%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
208.2B CHF |
76%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
251.4B USD |
79%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK |
82%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
209B USD |
68%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
143.2B USD |
75%
|
Ocular Therapeutix Inc
Glance View
Ocular Therapeutix Inc., nestled in the bustling biotechnology hub of Bedford, Massachusetts, is forging a new path in the ophthalmic treatment landscape. At its core, the company's mission pivots on the innovation and commercialization of novel therapies that address significant unmet needs in eye care. By leveraging its proprietary hydrogel technology, Ocular Therapeutix has developed a rich pipeline of both drug delivery and ophthalmic surgical products. Its flagship product, DEXTENZA, stands as a beacon of its innovative approach, offering an alternative to traditional drug delivery methods by releasing medication directly to the target site through a bioresorbable hydrogel implant. This targeted drug delivery not only enhances treatment efficacy but also addresses the age-old challenge of patient compliance in eye care, providing a significant competitive advantage in the market. Financially, Ocular Therapeutix develops its sustainability through a multi-pronged strategy that involves direct sales, licensing agreements, and strategic partnerships. Revenue is primarily generated from sales of its marketed products and milestones achieved through partnerships with other pharmaceutical companies. DEXTENZA and the upcoming products from its pipeline continue to chart new territory in securing market share by offering superior clinical outcomes. The company’s innovative technologies also open doors for licensing deals, providing a steady revenue stream as they partner with global firms that recognize the potential of personalized ophthalmic care. By threading together scientific innovation, strategic commercialization, and robust industry partnerships, Ocular Therapeutix positions itself not just as a biotech company, but as a transformative player aiming to redefine the ophthalmic treatment paradigm.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Ocular Therapeutix Inc's most recent financial statements, the company has Gross Margin of 88.9%.